Stock Ratings / Health Care / BVS / options

DRTS (33) PRCT (48) AORT (54) TNDM (35) ⌘ Pro Terminal →

Bioventus Inc. (Class A) (BVS) Options Positioning, Max Pain & Unusual Sweeps

$14.87 +1.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $14.88

Bioventus Inc. (Class A) (BVS) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 66/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.4% avg 90D alpha vs SPY) →

ROARABLE C+ • HOLD / WATCH Cap $1.25B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $14.88 (+0.08%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 12.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 66/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.4% avg 90D alpha vs SPY • 56.0% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+3.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BVS)Realized 20D OHLCV Swing Band: ±8.6%

Deterministic 5-Pillar Attribution (66/100 Composite)

🔍 WHY BVS SCORES 66/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (23% of score)

FRED Regime × Technicals: 89% of 52W Range • RSI-14 at 43.9 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (21% of score)

Altman Z-Score 2.25 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution12/20 pts (-8 pt drag)

Cannibal Buyback (-1.24% YoY Shares) & executive Form 4 sales trim 8 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$13.06+1.8% Next Q

Q2 (-2Q)

Grade C$13.30+12.5% Next Q

Q3 (-1Q)

Grade C+$14.96-0.6% Next Q

Current

Grade C+$14.87+1.4% Hist 90D α

Trajectory: C (58) → C+ (66)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the BVS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 66/100 (C+) score, BVS faces multiple-compression risk if 55.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 55x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 65.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($13.70) or 200D SMA ($10.90) invalidates the momentum regime and cuts Target Base ($15.41) toward Bear Floor ($12.02).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BVS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BVS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 66%NO 34%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±8.6%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (BVS)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for BVS.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating BVS & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on BVS
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BVS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +50.66%⚡ TESTING RESISTANCE

2026-10-30O $14.84H $14.87L $13.32C $14.87VOL 666.7K

RES: $15.36SUP: $12.85SMA50: $13.70SMA200: $10.90

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BVS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BVS Butterfly Map → + Track BVS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

39.0%/yr Implied 5Y Growth

vs. -0.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BVS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BVS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BVS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BVS)

Health Care Rank #129 of 1016 ⚔️ DRTS vs BVS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BVS vs. DRTS, PRCT, AORT, TNDM)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Bioventus Inc. (Class A) (BVS) ranks #129 by composite RQD confidence (66/100, grade C+) and #332 by equity capitalization ($1.25B). Within this direct 5-issuer industry benchmark cohort, BVS leads on earnings valuation at 55.0x trailing P/E, while BVS leads on capital efficiency and profitability with 10.4% ROIC and 68.3% gross margin. BVS currently leads its immediate peer cohort in composite quantitative strength at 66/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BVS ACTIVE Bioventus Inc. (Class A)	C+	66/100	55.0x	68.3%	10.4%	+1.50%	$1.25B	Benchmark Subject
DRTS Alpha Tau Medical Ltd.	E	33/100	—	—	-35.0%	-0.90%	$1.22B	/drts-vs-bvs →
PRCT PROCEPT BioRobotics Corporation	D	48/100	—	63.7%	-35.0%	+0.50%	$1.16B	/prct-vs-bvs →
AORT Artivion Inc.	D+	54/100	117.0x	64.4%	4.5%	+2.27%	$1.14B	/aort-vs-bvs →
TNDM Tandem Diabetes Care Inc.	D-	35/100	—	53.8%	-35.0%	+0.56%	$1.38B	/tndm-vs-bvs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001665988

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bioventus Inc. (Class A) (BVS) reported GAAP revenue of $568.1M (-0.9% vs. FY2024 revenue of $573.3M , and +10.9% cumulative change since FY2023) , GAAP net income of $22.7M, operating cash flow of $74.7M, and free cash flow of $72.1M (+90.8% YoY). On the balance sheet, BVS closed FY2025 with $683.6M in total assets against $279.0M in total debt (Altman Z-Score: 2.25, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$568.1M	$22.7M	$74.7M	$72.1M	$683.6M	$279.0M
FY2024 (FY)	2024-12-31	$573.3M	-$36.1M	$38.8M	$37.8M	$728.0M	$308.3M
FY2023 (FY)	2023-12-31	$512.3M	-$156.2M	$15.3M	$15.3M	—	—

3. BVS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BVS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Bioventus Inc. (Class A) (NASDAQ: BVS) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 66/100 at a spot price of $14.87 (+1.50% 1D, market cap $1.25B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, BVS ranks #129 in composite RQD confidence.

How does BVS compare to DRTS and PRCT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), BVS carries a Roarable C+ (66/100 RQD), trailing P/E of 55.0x, gross margin of 68.3%, and ROIC of 10.4%. By comparison, DRTS (Alpha Tau Medical Ltd.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $1.22B) and PRCT (PROCEPT BioRobotics Corporation) posts a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $1.16B). Among the 5-stock peer group, BVS leads on earnings multiple (55.0x) while BVS leads on capital efficiency (10.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BVS?

Per BVS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001665988), Bioventus Inc. (Class A) generated $568.1M in revenue (-0.9% YoY), $22.7M in net income, and $72.1M in free cash flow against $683.6M in total assets and $279.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Priced at 55x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BVS trading relative to its 50-day, 200-day, and 52-week technical levels?

BVS last traded at $14.87 (+1.50% on volume of 444,933 shares), positioning the stock +8.54% above its 50-day simple moving average ($13.70) and +36.42% above its 200-day simple moving average ($10.90). Across its 52-week range of $6.47 to $15.89, BVS sits at the 89.2% percentile with a 14-day RSI of 43.9 (NEUTRAL RANGE) and an implied next-earnings move of ±8.6% ($13.59 to $16.15).

BVS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is BVS's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for BVS.

Direct Sub-Reports: BVS RQD Cockpit BVS 12M Forecast BVS Earnings & Move BVS Dividends & DRIP BVS Insiders & 13F BVS Whale Options BVS Profit Sankey BVS News & Why